Xigduo · DIN 02449935 · 5 mg & 850 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: innoviCares lists Xigduo (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists Xigduo (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, September 10, 2026 ↗)
1 brand, same coverage
Xigduo · DIN 02449935
Manufacturer: AstraZeneca; listing date 2017-07-31
Health Canada: Marketed since 2016-02-08 · brand XIGDUO · ATC A10BD15 METFORMIN AND DAPAGLIFLOZIN, A10BD15 METFORMIN AND DAPAGLIFLOZIN · form Tablet · route Oral · ingredients DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) 5 MG, METFORMIN HYDROCHLORIDE 850 MG · company Astrazeneca canada inc · schedule Prescription
Ministry pays: $0.6432 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02449935)
Source record
DIN 02449935: Xigduo
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002063; group id 742; item number 1814; lccId None; manufacturer id AZC
Source form: Tab; strength: 5mg & 850mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $1.2863; ministry $0.6432
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02449935
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93580
Therapeutic Notes (formulary)
For the treatment of patients with type 2 diabetes mellitus who are already stabilized on therapy with metformin and dapagliflozin, to replace the individual components of dapagliflozin and metformin for those patients who have inadequate glycemic control on metformin, a contraindication or intolerance to a sulfonylurea, and for whom insulin is not an option.
Interchangeable products
Apo-Dapagliflozin-Metformin · DIN 02536153 · $0.6432
Auro-Dapagliflozin / Metformin · DIN 02533073 · $0.6432
Shortage status: resolved shortage (ended February 22, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02449935
Shortage record checked October 6, 2026